Evaluation of Brain Natriuretic Peptide in the Diagnosis of Heart Failure

Bettencourt, Paulo; Ferreira, António; Dias, Paula; Castro, Alice; Martins, Leopoldo Henrique Barboza; Cerqueira-Gomes, M

doi:10.1159/000006997

Cited by 61 publications

(40 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean (SE) BNP level was significantly increased in both the DHF (56 [30] pg/mL) and the SHF (154 [28] pg/mL) groups compared with controls (3 [38] pg/mL) (P = .02 and .001, respectively). The mean ANP level was also significantly increased in both the DHF and the SHF groups (34 [39] and 92 [98] pg/mL, respectively) compared with controls (14 [10] pg/mL) (P=.02 and .001, respectively). Both natriuretic peptides were increased significantly more in the SHF group than in the DHF group.…”

Section: Patient Characteristicsmentioning

confidence: 96%

Pathophysiological Characterization of Isolated Diastolic Heart Failure in Comparison to Systolic Heart Failure

Kitzman

Little²,

Brubaker³

et al. 2002

JAMA

767

593

View full text Add to dashboard Cite

show abstract

Section: Patient Characteristicsmentioning

confidence: 96%

Pathophysiological Characterization of Isolated Diastolic Heart Failure in Comparison to Systolic Heart Failure

Kitzman

Little²,

Brubaker³

et al. 2002

JAMA

767

593

View full text Add to dashboard Cite

show abstract

“…These authors found that, among the natriuretic peptides evaluated, BNP was the most accurate for the diagnosis of HF (accuracy of 96%). We evaluated the value of BNP in the diagnosis of HF in patients with mild to moderate symptoms (7). The accuracy of BNP for the diagnosis of HF, either with systolic or diastolic dysfunction, measured by the area under the ROC curve, was 92%.…”

Section: Bnp In the Diagnosis Of Hf And Asymptomatic Left Ventricularmentioning

confidence: 99%

Brain Natriuretic Peptide (Nesiritide) in the Treatment of Heart Failure

Bettencourt

2002

Cardiovascular Drug Reviews

Self Cite

View full text Add to dashboard Cite

Over the last decade brain natriuretic peptide (BNP) emerged as a cardiac hormone of clinical interest in diagnosis, prognosis and treatment of patients with Heart Failure (HF). The diagnostic potential of BNP is now well established both in patients with suspected HF as well as in patients with asymptomatic left ventricular systolic dysfunction. The prognostic information obtained from BNP levels in HF and acute myocardial infarction patients seems even more promising.Nesiritide is a synthetic peptide, homologous to endogenous BNP. It is a balanced vasodilator with diuretic and natriuretic properties. It decreases the elevated levels of neurohormones resulting from activation of the sympathetic and renin-aldosterone systems in HF. The results of clinical trials involving more than 2000 patients with decompensated HF are now available. In these trials nesiritide was administered by single or repeated bolus injections, as well as by sustained infusions.Nesiritide has been shown to produce a potent, dose-related vasodilator effect that is rapid in onset and sustained during infusion. Balanced vasodilation is reflected by decreases in systemic vascular resistance, pulmonary artery wedge pressure and right atrial pressure. No tachyphylaxis has been observed in these trials. Efficacy of nesiritide in the treatment of decompensated HF has been demonstrated. Trials comparing nesiritide with conventional treatment of decompensated HF showed that nesiritide compares favorably to standard agents. The safety profile has been excellent with a dose-dependent hypotension as the major side effect. Ventricular arrhythmia was not more frequent in patients treated with nesiritide than with placebo. Thus, nesiritide appears to be useful as a firstline agent in the treatment of patients with decompensated HF.

show abstract

“…Furthermore, the plasma BNP level is felt by some to be the most single accurate predictor of the presence or absence of congestive heart failure. Therefore, the BNP may be a more sensitive and specific indicator of ventricular disorders [2,3,4,5]. …”

Section: Introductionmentioning

confidence: 99%

The Relationship between Plasma BNP Level and the Myocardial Phosphocreatine/Adenosine Triphosphate Ratio Determined by Phosphorus-31 Magnetic Resonance Spectroscopy in Patients with Dilated Cardiomyopathy

Chida

Otani²,

Kohzuki

et al. 2006

Cardiology

View full text Add to dashboard Cite

The purpose of this study was to evaluate the correlation between the plasma B-type natriuretic peptide (BNP) level and the myocardial phosphocreatine/adenosine triphosphate ratio determined using rapid phosphorus-31 magnetic resonance spectroscopy (³¹P-MRS) in patients with dilated cardiomyopathy (DCM). Thirteen DCM patients, who had slight or moderate heart failure, were examined. The plasma BNP was measured on a day close to the rapid ³¹P-MRS study. ³¹P-MRS measurements were conducted with a 1.5-T MR instrument. The plasma BNP levels tended to be correlated negatively with the myocardial phosphocreatine/adenosine triphosphate, although the correlation did not reach statistical significance (r = –0.54, p =0.06). By contrast, the log of the plasma BNP levels was correlated negatively with the myocardial phosphocreatine/adenosine triphosphate (r = –0.73, p < 0.01). Our results indicate that the myocardial energy metabolism evaluated using ³¹P-MRS tends to be correlated with the severity of heart failure and left ventricular dysfunction estimated using the plasma BNP levels in DCM patients. This paper provides additional information regarding the relationship between the BNP and myocardial energy metabolism in DCM patients.

show abstract

Evaluation of Brain Natriuretic Peptide in the Diagnosis of Heart Failure

Cited by 61 publications

References 31 publications

Pathophysiological Characterization of Isolated Diastolic Heart Failure in Comparison to Systolic Heart Failure

Pathophysiological Characterization of Isolated Diastolic Heart Failure in Comparison to Systolic Heart Failure

Brain Natriuretic Peptide (Nesiritide) in the Treatment of Heart Failure

The Relationship between Plasma BNP Level and the Myocardial Phosphocreatine/Adenosine Triphosphate Ratio Determined by Phosphorus-31 Magnetic Resonance Spectroscopy in Patients with Dilated Cardiomyopathy

Contact Info

Product

Resources

About